Compare Novartis AG (NVS) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Veritone Inc — how do they compare? Novartis AG trades at $152.76 (market cap $295.37B), while Veritone Inc trades at $1.49 (market cap $138.04M). The key difference: Novartis AG is far larger — about 2139.7× Veritone Inc's market cap, and Novartis AG pays a 3.07% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| NVS | VERI | |
|---|---|---|
Market Cap | $295.37B | $138.04M |
Sector | Health | Technology |
52-Week High | $168.62 | $8.39 |
52-Week Low | $119.31 | $1.00 |
Enterprise Value | $336.69B | $170.07M |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Veritone (VERI) trades at $1.46, up 1.39% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported a net loss of $111.73M on $92.19M revenue in 2025, with negative profit margins and ROE. Recent news highlights partnerships in AI solutions, but a securities class action lawsuit deadline passed in July 2026.
Outlook remains challenged by persistent losses and high cash burn, offset by analyst optimism with 46% buy ratings. Key risks include the class action, profitability timeline, and competitive AI market. The stock's low price near support levels suggests high volatility potential amid mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
